CRSP - Company ID 0001674416
The table below shows CRISPR Therapeutics AG's balance sheet by quarter, as reported in the company's quarterly filings. All figures are in US dollars; negative values appear in red.
| Line item | Q3 2026 | Q2 2026 | Q1 2026 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $192.03M | $291.34M | $423.31M | $286.50M | $193.62M | $235.18M |
| Short-term investments | $2.08B | $2.07B | $2.02B | $1.63B | $1.53B | $1.62B |
| Receivables | - | - | - | $0.00 | $0.00 | $0.00 |
| Inventory | - | - | - | - | - | - |
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| Total current assets |
| $2.29B |
| $2.37B |
| $2.45B |
| $1.93B |
| $1.73B |
| $1.87B |
| Property, plant & equipment | $104.30M | $108.07M | $112.17M | $120.83M | $124.93M | $129.43M |
| Goodwill | - | - | - | - | - | - |
| Total assets | $2.56B | $2.65B | $2.73B | $2.25B | $2.03B | $2.17B |
| Accounts payable | $20.59M | $11.31M | $13.65M | $11.80M | $9.75M | $13.06M |
| Total current liabilities | $140.96M | $132.90M | $136.29M | $118.96M | $104.36M | $119.45M |
| Long-term debt | $586.93M | $586.20M | $585.47M | - | - | - |
| Total liabilities | $908.34M | $904.22M | $911.26M | $329.33M | $318.59M | $336.94M |
| Retained earnings | -$2.27B | -$2.16B | -$2.07B | -$1.82B | -$1.71B | -$1.50B |
| Total equity | $1.65B | $1.75B | $1.81B | $1.92B | $1.71B | $1.83B |